STVN Stock Analysis: Stevanato | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 5.517m USD | 12M Return: -20.1% | IT0005452658 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.27M
EPS Trend: 33.9%
Qual. Beats: 0
Rev. Trend: 97.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stevanato Group S.p.A. (NYSE: STVN) is an Italy-based provider of drug containment, drug delivery, and diagnostic solutions serving the global biopharma and healthcare industries. Founded in 1949 and headquartered in Piombino Dese, Italy, the company operates through two segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. Its product portfolio spans pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic consumables; drug delivery devices such as pen injectors, auto-injectors, and wearable injectors; visual inspection machines; glass converting and packaging equipment; and contract development and manufacturing services for customer-owned drug delivery devices. Stevanato serves pharmaceutical, biotechnology, diagnostics, and life sciences companies, as well as contract manufacturers, with operations spanning Europe, the Middle East, Africa, North America, South America, and Asia Pacific. The company is a subsidiary of Stevanato Holding S.R.L. and listed on the NYSE in July 2021.
The company operates within the healthcare equipment and pharma packaging subsector, supplying primary packaging components and integrated production machinery that are critical inputs for sterile injectable drug manufacturing, including biologics and vaccines. Its dual focus on proprietary glass containment products and engineering/contract manufacturing services positions it as a vertically integrated supplier to drug developers and fill-finish operations worldwide.
- GLP-1 packaging demand accelerates syringes and cartridge revenue
- Drug delivery systems revenue grows on auto-injector and wearable orders
- Capacity expansion pressures margins as customer ramps delay
- Schott Pharma and Gerresheimer competition intensifies in primary packaging
| Net Income: 134.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 5.09 > 1.0 |
| NWC/Revenue: 29.01% < 20% (prev 33.11%; Δ -4.10% < -1%) |
| CFO/TA 0.09 > 3% & CFO 247.0m > Net Income 134.2m |
| Net Debt (370.8m) to EBITDA (295.7m): 1.25 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (273.0m) vs 12m ago 0.03% < -2% |
| Gross Margin: 29.16% > 18% (prev 28.04%; Δ 1.12% > 0.5%) |
| Asset Turnover: 49.17% > 50% (prev 48.70%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 21.10 > 6 (EBIT TTM 200.5m / Interest Expense TTM 9.50m) |
| A: 0.14 (Total Current Assets 932.7m - Total Current Liabilities 578.3m) / Total Assets 2.62b |
| B: 0.39 (Retained Earnings 1.03b / Total Assets 2.62b) |
| C: 0.08 (EBIT TTM 200.5m / Avg Total Assets 2.49b) |
| D: 1.45 (Book Value of Equity 1.55b / Total Liabilities 1.07b) |
| Altman-Z'' = 4.23 = AA |
| DSRI: 1.05 (Receivables 539.7m/480.8m, Revenue 1.22b/1.15b) |
| GMI: 0.96 (GM 28.04% / 29.16%) |
| AQI: 0.91 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.07 (Revenue 1.22b / 1.15b) |
| TATA: -0.04 (NI 134.2m - CFO 247.0m) / TA 2.62b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 19.40 with a total of 267,095 shares traded. Over the past week, the price has changed by -3.96%, over one month by -4.15%, over three months by -1.77% and over the past year by -20.07%.
Current recommended Stop Loss: 18.20 (which is 6.2% or 1.4 ATR below the current price).
Stevanato has received a consensus analysts rating of 4.23. Therefore, it is recommended to buy STVN.
- StrongBuy: 7
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.7 | 27.2% |
Market Cap EUR = 4.92b (5.52b USD * 0.8918200135231 USD.EUR)
P/E Trailing = 36.0714
P/E Forward = 29.1545
P/S = 4.5009
P/B = 3.3343
P/EG = 1.5586
Revenue TTM = 1.22b EUR
EBIT TTM = 200.5m EUR
EBITDA TTM = 295.7m EUR
Long Term Debt = 312.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 123.9m EUR (from shortTermDebt, last quarter)
Debt = 454.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 11.3m
Net Debt = 370.8m EUR (calculated: Debt 454.3m - CCE 83.6m)
Enterprise Value = 5.29b EUR (4.92b + Debt 454.3m - CCE 83.6m)
Interest Coverage Ratio = 21.10 (Ebit TTM 200.5m / Interest Expense TTM 9.50m)
EV/FCF = -206.5x (Enterprise Value 5.29b / FCF TTM -25.6m)
FCF Yield = -0.48% (FCF TTM -25.6m / Enterprise Value 5.29b)
FCF Margin = -2.10% (FCF TTM -25.6m / Revenue TTM 1.22b)
Net Margin = 10.99% (Net Income TTM 134.2m / Revenue TTM 1.22b)
Gross Margin = 29.16% ((Revenue TTM 1.22b - Cost of Revenue TTM 865.6m) / Revenue TTM)
Gross Margin QoQ = 28.74% (prev 27.48%)
Tobins Q-Ratio = 2.02 (Enterprise Value 5.29b / Total Assets 2.62b)
Interest Expense / Debt = 2.09% (Interest Expense 9.50m / Debt 454.3m)
Taxrate = 29.95% (57.4m / 191.6m)
NOPAT = 140.4m (EBIT 200.5m * (1 - 29.95%))
Current Ratio = 1.61 (Total Current Assets 932.7m / Total Current Liabilities 578.3m)
Debt / Equity = 0.29 (Debt 454.3m / totalStockholderEquity, last quarter 1.55b)
Debt / EBITDA = 1.25 (Net Debt 370.8m / EBITDA 295.7m)
Debt / FCF = -14.47 (negative FCF - burning cash) (Net Debt 370.8m / FCF TTM -25.6m)
Total Stockholder Equity = 1.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.40% (Net Income 134.2m / Total Assets 2.62b)
RoE = 8.94% (Net Income TTM 134.2m / Total Stockholder Equity 1.50b)
RoCE = 11.06% (EBIT 200.5m / Capital Employed (Equity 1.50b + L.T.Debt 312.0m))
RoIC = 6.68% (NOPAT 140.4m / Invested Capital 2.10b)
WACC = 6.76% (E(4.92b)/V(5.37b) * Re(7.25%) + D(454.3m)/V(5.37b) * Rd(2.09%) * (1-Tc(0.30)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.73 | Cagr: 1.16%
[DCF] Fair Price = unknown (Cash Flow -25.6m)
EPS Correlation: 33.92 | EPS CAGR: 3.37% | SUE: 0.64 | # QB: 0
Revenue Correlation: 97.85 | Revenue CAGR: 5.22% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.18 | Chg30d=+0.50% | Revisions=-58% | Analysts=12
EPS current Year (2026-12-31): EPS=0.70 | Chg30d=-0.06% | Revisions=+21% | GrowthEPS=+12.4% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=0.84 | Chg30d=+0.15% | Revisions=+21% | GrowthEPS=+19.6% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: -3% (up=15, down=16)